Medical Centre Futuremeds EOOD
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Medical Centre Futuremeds EOOD, investigators are focusing on heart‑related conditions, aiming to improve outcomes for patients with heart failure with preserved ejection fraction and to lower the risk of major cardiac events.
- Heart failure with preserved or mildly reduced ejection fraction
- Coronary heart disease and myocardial infarction risk
- Lipoprotein(a)–driven atherosclerotic events
These studies test new therapeutic agents to reduce hospitalizations, prevent major cardiac events, and explore novel lipid‑lowering strategies.
Digestive System Diseases
Research at the centre addresses disorders of the gastrointestinal tract, especially inflammatory bowel disease and acid‑related esophageal injury.
- Moderately to severely active Crohn's disease
- Moderately to severely active ulcerative colitis
- Erosive esophagitis due to gastroesophageal reflux disease
Trials evaluate novel biologics and acid‑suppression agents to induce remission and maintain healing, seeking safer and faster symptom control.
Neoplasms
The oncology program explores treatments for solid tumors, including non‑small cell lung cancer and prostate cancers, as well as cancer‑associated weight loss.
- Non‑small cell lung cancer
- Metastatic castration‑sensitive prostate cancer
- Pancreatic cancer with cancer cachexia
Studies compare experimental antibody‑drug conjugates and targeted therapies with standard immunotherapy, aiming to extend survival and improve quality of life.
Nutritional and Metabolic Diseases
Investigators evaluate interventions for obesity and metabolic dysfunction, targeting weight reduction and metabolic health.
- Obesity
- Overweight with type 2 diabetes
- Body‑weight loss in cancer‑related cachexia
The trials test weekly injectable agents and hormone‑based compounds to achieve meaningful weight loss and improve metabolic markers.
Immune System Phenomena
Research includes modulation of immune pathways to enhance anti‑tumor responses and address autoimmune inflammation, focusing on immune checkpoint inhibitors.
- PD‑L1 high expression in lung cancer
- Combination of immune checkpoint inhibitors with novel agents
- Immune‑mediated gastrointestinal inflammation
These studies aim to boost the efficacy of immunotherapy while monitoring safety, offering new options for patients with immune‑driven disease.
Other Research Areas
A subset of studies explores mechanisms that do not fit traditional categories, focusing on translational science and biomarker validation.
- Biomarker validation for cardiovascular risk
- Exploratory safety assessments of first‑in‑human compounds
- Cross‑disciplinary investigations of metabolic‑immune interactions
These projects support the broader research agenda of the site, fostering innovative approaches that may inform future therapeutic development.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 7 therapeutic areas and 11 of 13 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 8 by active trials.
- 1F. Hoffmann-La Roche AG2active
lock +7 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1F. Hoffmann-La Roche AG3trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medical Centre Futuremeds EOOD
lock Showing 1 of 18 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Visugromab in Patients with Cancer-associated Cachexia | CatalYm GmbH | Phase IV | Recruiting | Mar 2026 | — |
IMP list
lock Showing 1 of 13 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ro7790121 | 3 | Unknown | 2025-01-09 | 2025-04-16 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.